Niagen Bioscience, Inc. Common Stock NAGE Business Segments
| Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Analytical Reference Standards and Services segment | $423K-45.2% | $772K-3.4% | $799K-1.5% | $811K+3.4% | $784K-0.9% | |
| Consumer Products segment | $22.41M-13.9% | $26.02M+14.6% | $22.7M+5.6% | $21.5M+18.6% | $18.12M-2.8% | |
| Corporate and other | $74K— | —— | —— | —— | —— | |
| Ingredients segment | $8.56M+19.0% | $7.2M-5.5% | $7.62M-6.7% | $8.17M+22.4% | $6.67M+102% | |
| Pharmaceuticals segment | $0— | —— | —— | $0— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Niagen Bioscience, Inc. Common Stock break its business down?
- Niagen Bioscience, Inc. Common Stock (NAGE) reports net sales by business across 5 parts — Analytical Reference Standards and Services segment, Consumer Products segment, Corporate and other, Ingredients segment and Pharmaceuticals segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Niagen Bioscience, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Niagen Bioscience, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
